A

Agilent Technologies, Inc.

Next est. report 2026-11-23 · AMC

Cycle Long '24: Health & Life SciencesGenomics '25: Genomics Tools & AutomationMedTech Long '24: Lab & Life Sciences Tools MedTech Long '26: Life Science Tools & Bioprocessing

Loading…

Loading chart…

Overview

Agilent Technologies provides specialized analytical instruments, software, and services for life sciences, diagnostics, and applied chemistry. Its segments off

Agilent Technologies provides specialized analytical instruments, software, and services for life sciences, diagnostics, and applied chemistry. Its segments offer tools like chromatography, mass spectrometry, and cell analysis for research, drug development, and quality control. Agilent CrossLab provides lab consumables and services. Serving diverse customers including pharmaceutical, biotech, chemical, and clinical labs, Agilent demonstrates strong performance through innovation.

Search Keywords Brand Product

Infinity III LC
9500 Triple Quad ICP-MS
Altura columns
Omnis family
Raman Insight series
life sciences tools
diagnostics research
applied chemistry
lab automation
bioprocessing
pharma reshoring
semiconductor investment
AI drug discovery
PFAS testing
GLP-1 drugs

Search Keywords Event Phrases

Agilent Q3 2026 earnings
ASMS conference
Biocare acquisition

Search Keywords Policy Regulatory

China stimulus
US biomanufacturing incentives
EU GMP Annex 1

What They Do (Plain English & Analogies): Agilent Technologies is like a high-tech detective agency for science and medicine. They provide sophisticated tools and services that help scientists and doctors figure out what things are made of, how they work, and if they're safe. For example, if a pharmaceutical company needs to ensure every pill has the right ingredients, Agilent provides the 'super-precise chemical detective kits' (analytical instruments like chromatography and mass spectrometry) to analyze it. If a doctor needs to diagnose cancer at a molecular level, Agilent offers 'genetic research tools' and specialized staining solutions. They also supply all the necessary lab supplies (consumables) and offer expert support, training, and software to keep these complex instruments running smoothly and delivering accurate results. Their technology is crucial for drug discovery, manufacturing quality control, cancer diagnostics, food safety, and environmental testing.
Very Brief History: Agilent Technologies, Inc. was established in 1999, having been spun off from Hewlett-Packard. Since its inception, the company has focused on delivering specialized technologies and services to the global life sciences, diagnostics, and applied chemistry industries, continually evolving its portfolio through innovation and strategic acquisitions.
"Street Stereotype": Agilent is generally perceived as a premium analytical instrumentation player, a high-quality company that directly benefits from a recovery in biotech funding. Investors and analysts often see it as a key beneficiary when lab capital expenditure budgets increase, particularly for quality assurance/quality control (QA/QC) and small-molecule workflows.
Subsidiaries On Linked In*: Biocare Medical — Acquired by Agilent Technologies, focuses on IHC lab testing and multiplex IHC tests for cancer and disease research and diagnostics.; LinkedIn: biocare-medical
Customer Sectors & Example Clients: Agilent's customers span a diverse range of sectors including: * **Pharma:** Large pharmaceutical companies (e.g., Pfizer, Eli Lilly, Novartis), biotech firms (large caps, small to mid caps), and those involved in GLP-1 drug development. The company secured reshoring orders from 5 of the top 10 pharma companies in the world in Q3 2026 alone. They also work with leading CXOs and a marquee local pharma customer in China. * **Chemical and Advanced Materials (CAM):** Semiconductor manufacturers (e.g., Intel, Samsung), high-purity chemical companies, and firms investing in chemical capital expenditures. * **Diagnostics and Clinical:** Hospitals, clinical pathology laboratories, and companies offering companion diagnostic services (e.g., Quest Diagnostics, LabCorp). * **Environmental and Forensics:** Government agencies (e.g., TSA for security screening), environmental testing laboratories, and forensic labs. A leading commercial testing lab in China chose Agilent for PFAS testing. * **Food:** Food manufacturers (e.g., Nestle, PepsiCo) and food safety testing laboratories. * **Academia and Government:** Research institutions, universities (e.g., Harvard, Stanford), and government-funded research bodies (e.g., NIH).
New Customers / Segments They'Re Targeting: Agilent is actively targeting several new customer sets and expanding into new segments. In China, they are focusing on biotech innovation, particularly with CXO customers and local biotech companies leveraging AI for drug discovery workflows. They are also seeing an inflection in contract testing laboratory volumes, especially for food safety and materials exports, and strong demand for their differentiated PFAS testing solutions. The company is expanding the Omnis family to bring laboratory automation to an entirely new customer set in pathology. Additionally, the recent Biocare acquisition expands their clinically focused antibody menu, complementing their pathology offering. The Raman Insight series is expanding its use cases from airport security checkpoints to other cities in the U.S., Europe, and beyond. They are also benefiting from semiconductor investment and broader AI infrastructure build-out, which positions them well for growth in advanced materials.
Supply Chain And Sourcing Geographies: Agilent's supply chain is global, with a strong focus on resilience and efficiency, driven by its Ignite operating system. The company has a significant manufacturing and R&D presence in China, highlighted by the launch of its China Innovation Center and localized manufacturing capabilities. They have also moved to a more agile, regionally led distributed manufacturing model, with regional hubs in Asia responding quickly to strong demand conditions. Agilent has implemented strategic manufacturing moves and targeted price adjustments to mitigate tariff impacts. The company's supply chain has demonstrated agility in responding to logistics challenges and material shortages, such as those arising from the Middle East conflict. While specific sourcing countries beyond China are not detailed, the global nature of its operations and the impact of geopolitical events suggest a diversified, yet exposed, sourcing network.
Sales Geographies And Expansion Plans: Agilent currently sells its products across major global regions. In Q3 2026, Americas grew 10%, Asia ex-China grew 9%, and China grew 9%. Europe grew low single digits. The company is focused on strengthening its market share and presence within its existing geographies. In China, they are expanding through their Innovation Center and localized go-to-market capabilities. They are also optimistic that the opportunity for their Raman Insight series (aviation security products) could expand through further RFPs in the U.S. and adoption in Europe and beyond.
How Key Themes May Help/Hurt: Agilent is well-positioned to benefit significantly from the 'MedTech Long '26: Life Science Tools & Bioprocessing' theme. The recovery in biotech venture capital funding directly translates into increased R&D spending, boosting demand for Agilent's analytical instruments, reagents, and lab services. The surging demand for GLP-1 therapeutics is a strong tailwind, with Agilent's GLP-1 momentum delivering over 70% year-over-year growth in Q3 2026 from both its CDMO and analytical lab businesses. Accelerated pharma reshoring and increased CDMO outsourcing are fueling a multi-year investment cycle, and Agilent has already booked initial reshoring orders and expects more meaningful order benefits around year-end, with revenue contributions building in fiscal 2027 and beyond. The integration of AI is also accelerating drug discovery and development, aligning with Agilent's enterprise AI strategy and partnerships in its China Innovation Center. However, the theme also presents potential challenges. Persistent geopolitical tensions and continued weakness in certain parts of the China market (though Agilent saw a notable step-up in Q3) could introduce headwinds. While small to mid-cap biotech spending is returning, a significant lag in translating funding into actual customer spending for capital equipment could still impact some areas. Additionally, ongoing inflationary pressures, such as those from the Middle East conflict and demand for memory chips, could increase operational costs, although Agilent's Ignite Operating System is designed to mitigate these impacts through efficiencies and strategic pricing.

3 Main Long-Term Bull Details

Compounding Benefits of Ignite Operating System: Agilent's Ignite operating system is structurally embedding operational and P&L benefits, driving significant margin expansion (210 basis points year-over-year in Q3 2026 excluding tariff refunds) and strong pricing realization (approximately 200 basis points in Q3 2026). This operational excellence, including supply chain agility and manufacturing excellence, contributes to robust EPS growth and positions Agilent for durable long-term profitability.
Robust Innovation and Instrument Replacement Cycles: Agilent continues to drive market share gains through a continuous cadence of customer-centric innovations, such as the Infinity III LC, 9500 Triple Quad ICP-MS, and new flagship GC systems (8890B and 8860B). These innovations fuel strong instrument replacement cycles, with LC revenue growing low double digits and GC showing low single-digit growth in Q3 2026, ensuring continued installed base growth and recurring consumables and services pull-through.
Diversified Portfolio Aligned with Key Growth Trends (Pharma Reshoring, GLP-1, AI, Semiconductor): Agilent's broad portfolio is strategically positioned across resilient end markets. Pharma grew 12% in Q3 2026, driven by strong GLP-1 momentum (over 70% growth) and the beginning of U.S. reshoring orders. The company is also benefiting from semiconductor investment and broader AI infrastructure build-out, underpinning robust growth in advanced materials, and leveraging AI to transform software development and customer journeys.

3 Main Long-Term Bear Details

China Market Volatility and Geopolitical Headwinds: Despite a strong Q3 2026 performance in China, the market has experienced significant volatility, and geopolitical tensions (e.g., Middle East conflict) can lead to logistics challenges and material shortages. While Agilent's localized presence helps, sustained shifts in policy or increased local competition could impact long-term growth and profitability in this crucial region.
Muted Academia and Government Spending: The Academia and Government end market remains a smaller and more volatile segment for Agilent, declining 3% in Q3 2026. Persistent budgetary constraints and slower government funding in various regions could act as a drag on overall growth, particularly for capital equipment sales.
Inflationary Pressures and Tougher Comparisons: Agilent faces ongoing inflationary cost pressures, including those from the Middle East conflict and demand for memory chips. While the Ignite Operating System is designed to mitigate these, sustained high inflation could challenge margin expansion. Additionally, the company is facing increasingly tougher year-over-year comparisons in the latter half of fiscal year 2026, which could moderate growth rates despite strong underlying performance.

Competitors And Differentiation: Agilent emphasizes its unparalleled customer intimacy and trust as a key differentiator, which translates into share gains across key workflows and geographies. They offer a differentiated portfolio and best-in-class service. For PFAS testing, their complete end-to-end workflows, from sample preparation and analytical instrumentation to application and regulatory expertise, enable them to win against competitors. Agilent also highlights its leadership across the applied markets and the strength of its installed base. They are the #1 player in the Chemical and Advanced Materials (CAM) market by far, with substantial leadership positions in GC, GC/MS, and spectroscopy. The company expects to sustainably outperform the competition.
Recent Performance & What The Market'S Focused On: Agilent delivered an excellent third quarter of fiscal year 2026, with revenue of $1.88 billion, growing 7.3% on a core basis and exceeding guidance. Operating margin, excluding tariff refunds, was 27.2%, 80 basis points ahead of implied guidance, and EPS of $1.56 (ex-refunds) was $0.06 above the high end of guidance, representing 14% year-over-year growth. The market is focused on several key areas: the sustained momentum and compounding benefits of the **Ignite Operating System** in driving margin expansion and strategic pricing; the continued strength of **instrument replacement cycles** (LC and GC) and the success of **new product launches** (e.g., 9500 ICP-MS, Altura columns); the **recovery and growth in the China market**, which saw a notable step-up in Q3; the materialization of **pharma and semiconductor reshoring orders**; the robust performance of the **specialty CDMO (Advanced Therapeutics Division)**, particularly with GLP-1 demand and the upcoming Train C capacity expansion; and the overall **margin trajectory** given the strong Q3 performance and ongoing inflationary pressures.

Revenue Segments And Estimated Mix: Life Sciences and Diagnostics Markets Group (LDG) — Mix: n/m; Source: Q3 2026 transcript; Trend: Grew 10% core in Q3 2026, nicely ahead of expectations. Full year FY26 guidance raised to mid- to high single-digit growth. Includes Advanced Therapeutics Division (nearly 30% growth in Q3) and cancer diagnostics business.
Applied Markets Group (AMG) — Mix: n/m; Source: Q3 2026 transcript; Trend: Grew 7% core in Q3 2026, well ahead of expectations. Full year FY26 guidance raised to mid- to high single-digit growth. Led by high single-digit increase in spectroscopy and double-digit performance in vacuum.
Agilent CrossLab Group (ACG) — Mix: n/m; Source: Q3 2026 transcript; Trend: Grew north of 5% core in Q3 2026, modestly ahead of forecast. Driven by strong performance in consumables. Full year FY26 guidance remains mid-single-digit growth.
Product Brands: Infinity III LC
8850 GC
9500 Triple Quad ICP-MS
8890B GC
8860B GC
Altura columns
Ultra columns
Elite columns
OpenLab CDS
Omnis family
SureSelect
Magnis
Bravo
NeoPATH Pro™
ONCORE Pro®
ONCORE Pro X
intelliPATH Plus®
Raman Insight series
Insight BRT
Insight300

Bull / Bear Details

Agilent's Q3 2026 results strongly validate its long thesis, driven by accelerating momentum from the Ignite operating system, delivering significant margin exp

Thesis

Agilent's Q3 2026 results strongly validate its long thesis, driven by accelerating momentum from the Ignite operating system, delivering significant margin expansion and double-digit EPS growth. Robust instrument replacement cycles, innovation-led share gains, and the notable turnaround in China, coupled with early pharma reshoring benefits and strong GLP-1 demand, position Agilent for durable outperformance. (Updated: 2026-08-28)

Bull case

The Ignite operating system continues to drive exceptional financial performance, with Q3 strategic pricing delivering approximately 200 basis points and operating margin (excluding tariff refunds) expanding 210 basis points year-over-year. This operational excellence has enabled Agilent to raise its full-year EPS guidance to 10% growth, demonstrating superior execution and structural improvements across the business.
Agilent benefits from robust, diversified growth drivers, including 12% pharma growth (over 70% GLP-1, double-digit biotech), strong instrument replacement cycles (low double-digit LC growth), and successful new product launches like the 9500 ICP-MS and Altura columns. Initial pharma reshoring orders from five of the top ten global pharma companies further bolster future revenue.
The significant turnaround in China, with 9% growth against flat expectations, signals renewed momentum driven by strong commercial execution, biotech innovation, and increasing demand for PFAS testing. Emerging AI capital investment and Agilent's strategic AI initiatives across workflows, including partnerships with OpenAI and BCG X, also present substantial long-term growth opportunities.

Bear case

While the long-term outlook for the Advanced Therapeutics Division (CDMO) remains strong, flattish growth is expected in Q4 2026 due to a challenging year-over-year comparison of over 40%. This near-term deceleration in a high-growth segment, even with Train C capacity largely booked for FY27, could temper overall growth expectations.
The Academic and Government segment continues to decline (3% in Q3), and the Food market remains largely flat, indicating persistent softness in these smaller end markets. Additionally, ongoing inflationary cost pressures from the Middle East conflict and demand for memory chips continue to pressure Agilent's costs, potentially challenging future margin expansion.
Despite overall strong performance, Europe's low single-digit growth on a tough year-over-year comparison highlights regional disparities that could persist. While China has rebounded, potential future policy shifts or increased local competition could impact its sustained momentum. Regulatory uncertainties, particularly for new drug modalities, could also introduce headwinds.

Bull / Bear Case

Bear Case: Despite strong Q3 results, the Advanced Therapeutics Division (CDMO) is expected to see flattish growth in Q4 2026 due to a challenging year-over-year comparison of over 40%, potentially tempering overall growth expectations. Smaller end markets like Academic and Government (declined 3%) and Food (roughly flat) continue to show softness. Ongoing inflationary cost pressures from the Middle East conflict and demand for memory chips persist, which could challenge future margin expansion. Europe's low single-digit growth on a tough year-over-year comparison highlights regional disparities. While China has rebounded, potential future policy shifts or increased local competition could impact its sustained momentum, and regulatory uncertainties for new drug modalities introduce headwinds.
Bull Case: Agilent's Ignite Operating System continues to drive exceptional financial performance, delivering approximately 200 basis points in strategic pricing and 210 basis points in operating margin expansion (ex-tariff refunds) in Q3 2026, leading to a raised full-year EPS growth target of 10%. The company benefits from robust, diversified growth drivers, including 12% pharma growth (over 70% GLP-1, double-digit biotech), strong instrument replacement cycles (low double-digit LC growth), and successful new product launches. A significant turnaround in China, with 9% growth against flat expectations, signals renewed momentum driven by biotech innovation and increasing demand for PFAS testing. Initial pharma reshoring orders from five of the top ten global pharma companies further bolster future revenue, with AI initiatives presenting long-term growth opportunities.
More Compelling & Why: Bear. Given the stock's neutral post-earnings performance (0.00% return vs. SPY's 0.55%) despite strong results, the market appears to have already priced in much of the good news. If Agilent's P/E ratio is trading above its industry average (e.g., 35x vs. 28-30x), the valuation seems stretched. The strongest bear argument is the near-term deceleration in the high-growth CDMO segment and persistent inflationary pressures, which could limit further upside from current valuation levels. My view would flip to bullish if the stock's P/E compressed closer to industry averages without fundamental deterioration, or if FY27 growth guidance significantly exceeded current expectations.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Diagnostics and Clinical Segment Growth and Biocare Integration	The Diagnostics and Clinical segment provides diversification and exposure to growing areas like cancer diagnostics and pathology. Successful integration of acquisitions like Biocare enhances Agilent's portfolio and market position.	Monitor the Diagnostics and Clinical core growth rate in Q4 2026 (Q3 was 6%). Track Biocare's revenue contribution in Q4 2026 (expected $23 million) and commentary on the integration progress and underlying order growth in pathology.	Bullish: Diagnostics and Clinical growth accelerates or remains strong, supported by Biocare's contribution. Successful integration of Biocare. Bearish: Deceleration in segment growth or reported challenges with Biocare integration.	Company earnings calls and press releases for Q4 2026 (expected late November 2026).	Industry news on cancer diagnostics and pathology market trends. ClinicalTrials.gov: New clinical trials for companion diagnostics.	IQVIA: Diagnostics market data. AlphaSense: Mentions of 'Biocare Medical' and 'Agilent Diagnostics' in industry reports. S&P Global Market Intelligence: M&A integration success metrics for similar deals.
Ignite Operating System Impact on Operating Margin and Pricing	The Ignite Operating System is structurally embedding operational and P&L benefits, driving strategic pricing and manufacturing excellence. This leads to significant operating margin expansion and financial flexibility, crucial for profitability and shareholder value.	Monitor the full-year 2026 operating margin expansion target (excluding tariff refunds), which was increased to 'over 100 basis points'. Track strategic pricing contribution, which delivered approximately 200 basis points in Q3 2026.	Bullish: Full-year operating margin expansion (ex-tariff refunds) exceeds 100 basis points. Strategic pricing contribution remains at or above 200 basis points. Bearish: Operating margin expansion falls below 100 basis points or pricing contribution declines.	Company earnings calls and press releases for Q4 2026 (expected late November 2026).	N/A	FactSet / Bloomberg: Consensus estimates for operating margin. S&P Global Market Intelligence: Peer comparison on operating margins.
China Market Recovery and Momentum	China is a critical growth market for Agilent. Its significant turnaround from a Q2 decline to 9% growth in Q3 2026 indicates effective localized strategy and successful capture of emerging opportunities, offsetting previous headwinds.	Observe China revenue growth rate in Q4 2026 (guided high single digits) and management commentary on sustained momentum into fiscal year 2027. Track full-year 2026 China growth expectations (raised to mid-single digits).	Bullish: China revenue growth sustained at high single digits or higher in Q4 2026 and into FY27. Bearish: Deceleration or a return to flat/negative growth in China.	Company earnings calls and press releases for Q4 2026 (expected late November 2026).	China National Bureau of Statistics: Industrial output data for relevant sectors (pharma, chemicals). Google Trends: 'Agilent China' search volume. Baidu Index: Search trends for Agilent products in China.	Sensor Tower / Apptopia: Usage trends for Agilent's digital platforms in China. Thinknum: Job postings in China for Agilent.
Pharma End Market Performance: U.S. Reshoring Orders and GLP-1 Momentum	The materialization of U.S. pharma reshoring orders represents a multi-year incremental instrument growth opportunity, while sustained GLP-1 demand drives robust growth for Agilent's CDMO and analytical lab businesses. These factors indicate strong underlying demand and Agilent's ability to capture high-growth therapeutic areas.	Monitor for 'more meaningful order benefit from pharma reshoring around year-end', with revenue contributions building in fiscal year 2027 and beyond. Track continued GLP-1 related revenue growth, which was over 70% year-over-year in Q3 2026.	Bullish: Continued booking of reshoring orders from top pharma companies and confirmed revenue contributions in FY27. GLP-1 growth sustained at or above 70% year-over-year. Bearish: Delays in reshoring revenue or a significant deceleration in GLP-1 growth.	Company earnings calls and press releases for Q4 2026 (expected late November 2026) and Q1 2027 earnings.	USASpending.gov: Government contract awards related to pharmaceutical manufacturing. Industry news on new pharma facility constructions. EvaluatePharma: Summaries of GLP-1 drug sales data.	Revere: Pharma R&D spend by region. AlphaSense: Mentions of 'pharma reshoring' and 'GLP-1' in competitor transcripts. IQVIA: GLP-1 prescription data.
Instrument Revenue Growth and New Product Adoption	Sustained high single-digit instrument revenue growth, driven by LC/GC replacement cycles and strong adoption of new products like the 9500 ICP-MS, flagship GCs, and Altura columns, indicates robust customer demand and market share gains. This builds the installed base for future recurring consumables and service revenue.	Observe if the instrument book-to-bill ratio remains consistently above 1 (it was above 1 for the 10th consecutive quarter in Q3 2026). Track the funnel for the 9500 ICP-MS (exceeded $60 million in Q3) and orders for new GCs (exceeded 2x expectations in Q3). Monitor Altura column growth in new biopharma accounts (28% quarter-over-quarter growth in Q3).	Bullish: Book-to-bill ratio remains above 1. Continued strong order funnels and adoption rates for new instruments and columns. Bearish: Deceleration in instrument growth or book-to-bill ratio falling below 1.	Company earnings calls and press releases for Q4 2026 (expected late November 2026).	Google Trends: Search volume for 'Agilent 9500 ICP-MS', 'Agilent GC', 'Altura columns'. Industry forums/blogs discussing new lab equipment.	Technomic: Lab equipment purchasing trends. AlphaSense: Mentions of specific Agilent products in industry reports. Gartner: Market share reports for analytical instruments.

Key Reported Metrics, Reratings Triggers & Results3 rows

This metric highlights Agilent's profitability and operational efficiency, particularly the compounding benefits of the Ignite operating system in offsetting co

Upcoming print · 2026-11-23

Key reported metrics
Metric	Last period	Why it matters
Operating Margin (ex-tariff refunds) YoY Growth	8.4%	This metric highlights Agilent's profitability and operational efficiency, particularly the compounding benefits of the Ignite operating system in offsetting cost pressures and driving value creation.
China Revenue Growth	9%	China's significant turnaround and sustained momentum are crucial for Agilent's overall growth trajectory, especially given its prior decline and the potential for continued strong performance in a key region.
Pharma Segment Revenue Growth	12% y/y growth	Pharma's performance, driven by biotech recovery, GLP-1 momentum, and U.S. reshoring, is a critical indicator of Agilent's ability to capitalize on high-growth therapeutic areas and drive future revenue.

Last reported · 2026-08-26

Key reported metrics			Rerating thresholds			Earnings results
Metric	Last period	Why it matters	What's needed for rerating	Rerating context	Earnings date	Actual reported	Hit target?	Notes
Pharma Segment Revenue Growth	6%	As a key end market, Pharma's performance, driven by biotech recovery, GLP-1 momentum, and U.S. reshoring, is a critical indicator of Agilent's ability to capitalize on high-growth therapeutic areas.	The Pharma Segment Revenue Growth metric needs to hit 10% or more for the upcoming Q3 2026 earnings report. This would represent a significant acceleration from the 6% reported in Q2 2026 and surpass management's expectation of 'high single-digit growth' for the pharma segment.	Achieving double-digit Pharma Segment Revenue Growth validates Agilent's investment thesis by demonstrating strong execution in high-growth therapeutic areas like GLP-1s and biotech recovery. This signals innovation-led share gains and robust demand, driving a positive re-evaluation of its long-term growth and competitive position.	2026-08-26	12% y/y growth	Yes	The Pharma segment grew 12% in the quarter, significantly exceeding the rerating trigger of 10% or more and management's high single-digit expectations. This strong performance was driven by double-digit growth in biotech and mid-single-digit growth in small molecule, with GLP-1 momentum contributing over 70% growth.
Non-GAAP EPS Growth	14%	This highlights Agilent's profitability and operational efficiency, particularly the compounding benefits of the Ignite operating system. Strong EPS growth signals effective cost management and value creation.	Non-GAAP EPS Growth needs to hit 10% or more year-over-year for Q3 2026, specifically if it results in Non-GAAP EPS of at least $1.51. This would exceed Agilent's Q3 2026 guidance of $1.48 to $1.50 and current analyst consensus estimates of $1.48.	Exceeding EPS expectations and reaffirming double-digit growth signals strong operational execution and the compounding benefits of Agilent's Ignite operating system. This validates the investment thesis, demonstrating superior profitability and value creation, reinforcing investor confidence and driving a positive rerating.	2026-08-26	$1.56 (14% y/y growth)	Yes	Agilent reported Non-GAAP EPS of $1.56 (excluding tariff refunds), which represents 14% year-over-year growth. This exceeded the high end of their guidance range of $1.48 to $1.50 and the rerating trigger of at least $1.51 and 10% growth.
Core Revenue Growth	6.3%	This metric indicates the overall top-line health and market demand for Agilent's diverse portfolio. Sustained growth reflects successful innovation and market share gains, crucial for investor confidence.	Core Revenue Growth needs to hit above 6.0% for the upcoming Q3 2026 earnings report, exceeding Agilent's guidance of 4.4% to 5.9%.	Exceeding 6.0% core revenue growth validates Agilent's durable long-term growth thesis, driven by strong instrument cycles and innovation. It signals robust market demand, reinforces investor confidence in operational excellence, and could trigger a positive re-rating after the previous quarter's muted market reaction.	2026-08-26	$1.88 billion (7.3% y/y growth)	Yes	Agilent reported $1.88 billion in revenue, representing 7.3% core growth, which surpassed the rerating trigger of above 6.0% and exceeded the high end of their guidance by 140 basis points.

Key Questions

Can Agilent sustain the strong momentum in its China market, which saw 9% growth in Q3 2026, and translate this into continued mid-to-high single-digit growth f

Can Agilent sustain the strong momentum in its China market, which saw 9% growth in Q3 2026, and translate this into continued mid-to-high single-digit growth for fiscal year 2027, particularly given minimal prior stimulus benefit and ongoing geopolitical dynamics?

Question 2: Will the Ignite Operating System continue to deliver significant operating margin expansion (exceeding the raised full-year target of over 100 basis points) and fully offset persistent inflationary pressures and tough year-over-year comparisons in Q4 2026?
Question 3: How quickly will the initial pharma and semiconductor reshoring orders translate into meaningful revenue contributions in fiscal year 2027 and beyond, and can the Advanced Therapeutics Division successfully ramp up Train C capacity to sustain mid-teens growth despite a flattish Q4 2026 outlook?

Earnings Transcript Summary2 rows

2026-08-26 · 2026Q3 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Leveraging the Ignite Operating System: Management emphasized Ignite as the core engine driving operational excellence, strategic pricing (delivering approximately 200 basis points in Q3), manufacturing resilience, supply chain agility, and the development of next-generation digital and AI capabilities across the company. 2. Customer Intimacy, Innovation, and Market Share Gains: Agilent is focused on building unparalleled customer intimacy, which informs its innovation engine, leading to distinct solutions and share gains across key workflows and geographies. This is evident in the strong demand for new product launches like the 9500 ICP-MS, flagship GC systems, and Altura columns. 3. Capitalizing on Key Growth Drivers and Improving End Markets: Management highlighted strong commercial execution against improving conditions in largest end markets, including Pharma (driven by GLP-1 momentum, biotech recovery, and reshoring), Applied Markets (benefiting from semiconductor investment and AI infrastructure), and Diagnostics. They are also focused on the ongoing instrument replacement cycle and the materialization of reshoring dynamics.	Call Takeaway & ToneThe overall takeaway of the call was highly positive, reflecting Agilent's excellent third-quarter performance that exceeded both top and bottom-line guidance. The company demonstrated strong commercial and operational execution, with the Ignite Operating System driving significant margin expansion and structural improvements. Key themes included the notable acceleration in China revenue, robust growth in the pharma segment (especially GLP-1s and biotech), early materialization of reshoring orders, and the success of new product innovations. Management expressed strong confidence in the business's momentum and its ability to deliver durable, above-market growth, leading to a raised full-year guidance for both revenue and EPS. The tone was optimistic and confident, with management frequently using terms like "excellent," "strong," "robust," and "outstanding" to describe their results and outlook.	Prior Quarter'S Y/Y Growth By SegmentIn Q2 2026, Agilent's overall core revenue grew 6.3%, accelerating to 7.3% in Q3 2026. Pharma grew 6% in Q2 2026, accelerating to 12% in Q3 2026. The Advanced Therapeutics Division (ATD) grew high single-digits in Q2 2026, accelerating to nearly 30% in Q3 2026. Chemical and Advanced Materials (CAM) grew 8% in Q2 2026, decelerating to 7% in Q3 2026. Environmental and Forensics grew 13% in Q2 2026, decelerating to 5% in Q3 2026. Diagnostics and Clinical grew 11% in Q2 2026, decelerating to 6% in Q3 2026. Food declined 3% in Q2 2026, improving to roughly flat in Q3 2026. Academic and Government declined 5% in Q2 2026, improving to a 3% decline in Q3 2026. Applied Markets Group (AMG) grew 11% in Q2 2026, decelerating to 7% in Q3 2026. Life Sciences and Diagnostics Markets Group (LDG) grew 9% in Q2 2026, accelerating to 10% in Q3 2026. Agilent CrossLab Group (ACG) grew 2% in Q2 2026, accelerating to north of 5% in Q3 2026. China revenue declined 9% in Q2 2026, showing a significant turnaround to 9% growth in Q3 2026.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Specialty CDMO (Advanced Therapeutics) Business Outlook and Margins: Analysts inquired about the visibility of the nearly 30% growth in the CDMO business into 2027 and its margin dynamics. Management responded that they remain confident in a mid-teens growth rate over the long-range plan, with Train C coming online in spring 2027 and the majority of its capacity already booked. They stated that margins should align with the broader business at full capacity, and any negative margin impact from the Train C ramp-up would be mitigated by the Ignite Operating System. 2. Reshoring Opportunity and Quantification: Analysts pressed for quantification of the initial reshoring orders, changes to the $1 billion industry expectation, and expected contributions for fiscal year 2027. Management reiterated the $1 billion opportunity through 2030, expecting to win at least one-third. They confirmed booking initial reshoring orders in Q3 from 5 of the top 10 global pharma companies, ahead of expectations, and clarified that instrument and service revenues from reshoring are incremental, with revenue contributions building in fiscal 2027 and beyond. 3. China Market Strength and Drivers: Analysts sought more detail on the significant turnaround in China, which grew 9% against flat expectations, asking about the drivers (e.g., local customers, multinationals, biotech, stimulus). Management attributed the strength to strong execution with commercial accounts, particularly in pharma (double-digit growth in biotech and small molecule, GLP-1 testing) and food (mid-teens growth), competitive wins, and emerging growth drivers like biotech innovation, contract testing lab volumes (PFAS), and AI capital investment. They noted minimal China stimulus benefit in Q3 but see momentum continuing.	Revenue SegmentsOverall core revenue grew 7.3%. Pharma revenue grew 12%, with biotech growing double digits and small molecule growing mid-single digits. The Advanced Therapeutics Division (ATD) grew nearly 30%, and GLP-1 momentum delivered over 70% growth. Chemical and Advanced Materials (CAM) grew 7%, with advanced materials showing double-digit growth and environmental and forensics growing 5% (PFAS grew 20%). Diagnostics and Clinical grew 6%, with CDx growing mid-teens and genomics growing high single digits. Food was roughly flat. Academic and government declined 3%. Geographically, China grew 9%, Asia ex-China grew 9%, Americas grew 10%, and Europe grew low single digits. Instrument revenue saw high single-digit growth, including low double-digit growth in LC and low single-digit growth in GC. Segment-wise, Life Sciences and Diagnostics Markets Group (LDG) grew 10% on a core basis, Applied Markets Group (AMG) grew 7% on a core basis (including high single-digit spectroscopy and double-digit vacuum growth), and Agilent CrossLab Group (ACG) grew north of 5% on a core basis (with mid-single-digit service and high single-digit consumables growth).

2026-05-27 · 2026Q2 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused OnManagement is most focused on: 1. Leveraging the Ignite operating system: This system is structurally embedding operational and P&L benefits, driving strategic pricing (200 basis points in Q2), productivity initiatives, supply chain agility, and manufacturing excellence. It also accelerated the launch of the 9,500 ICPMS by a full quarter. 2. Customer intimacy, innovation, and market share gains: Agilent is emphasizing its strong customer relationships, which translate into insights for innovation, leading to new product launches (e.g., Infinity III LC, 8850 GC, 9,500 triple quad ICPMS, upgraded GCs, Altura columns, OpenLab CDS Version 3.0) and resulting in share gains across key workflows and geographies. 3. Capitalizing on strong end-market momentum and strategic growth drivers: Management highlighted continued health in key end markets like Pharma (especially biotech and GLP-1s), Chemical and Advanced Materials (semiconductor demand), Diagnostics and Clinical (cancer diagnostics, Omnis family), and Forensics (TSA contract). They are also focused on the instrument replacement cycle and strategic M&A like the Biocare acquisition.	Call Takeaway & ToneThe overall takeaway of the call was highly positive, reflecting strong execution and outperformance in Q2 2026. Management expressed confidence in the company's ability to deliver durable growth and margin expansion, largely driven by the compounding benefits of its Ignite operating system, robust innovation, and strong commercial execution. The tone was optimistic, with management raising full-year guidance for both revenue and EPS, despite facing tougher comparisons in the second half and some inflationary pressures. Key themes included significant market share gains, the success of new product launches, the ongoing instrument replacement cycle, and the strategic impact of the Ignite system on both top-line momentum and profitability.	Prior Quarter'S Y/Y Growth By SegmentIn Q1 2026, Agilent's core revenue growth was 4.4% [1, 2]. Segment-wise, Agilent CrossLab Group (ACG) grew 6% [1, 2]. Applied Markets Group (AMG) grew 4% [1, 2]. Life Sciences and Diagnostics Markets Group (LDG) grew 3% [1, 2]. Diagnostics and Clinical grew 7% [3]. Environmental and Forensics was flat (0%) [3]. Food declined 4% [3, 4]. Academia and Government declined 8% [3, 4]. Pharma and Chemical and Advanced Materials (CAM) were not explicitly stated with a specific growth percentage but were described as having a 'strong start' in Q1 2026 [1, 2]. Comparing Q2 2026 to Q1 2026: AMG accelerated from 4% to 11%. LDG accelerated from 3% to 9%. ACG decelerated from 6% to 2%. Diagnostics and Clinical accelerated from 7% to 11%. Environmental and Forensics accelerated from 0% to 13%. Food improved from -4% to -3%. Academia and Government improved from -8% to -5%.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. CAM strength and Academia & Government (A&G) trends: Analysts inquired about the sustainability of CAM's strong performance and the trends in A&G. Management responded that CAM grew 8% (ex-China low teens), driven by increased CapEx in semiconductors and strong leadership in platforms, and they don't see a slowdown. For A&G, they expected a -5% decline in Q2, which was in line, with some signs of stability returning in the Americas due to redistributed funds. 2. Margins and Q4 ramp: Analysts questioned the impressive margin print and visibility into the Q4 margin ramp. Management attributed the margin beat to the Ignite operating system (including over 200 bps of pricing, execution excellence, structural improvements, and procurement savings) and favorable geographic mix. They expressed confidence in the Q4 ramp, stating it's consistent with historical H1 to H2 operating profit splits. 3. Specialty CDMO (Advanced Therapeutics) visibility and instrument strength: Analysts asked about the visibility of the mid-teens growth target for Advanced Therapeutics in the second half and the durability of instrument strength. Management confirmed strong visibility for the H2 uptick, with production schedules pointing to strong Q3 and the mechanical completion of Train C on schedule for spring 2027. They noted instrument strength (low double-digit growth in LC, LC/MS, and GC) is driven by the ongoing replacement cycle (a 200-300 bps tailwind for LC and 100 bps for GC), market share gains, and compelling customer-focused innovations.	Revenue SegmentsAgilent reported Q2 2026 revenue of $1.83 billion, growing 6.3% on a core basis. Segment-wise, Applied Markets Group (AMG) revenue grew 11% on a core basis. Life Sciences and Diagnostics Markets Group (LDG) revenue grew 9% on a core basis, with low double-digit growth in LC and LC/MS, and in cancer diagnostics. Agilent CrossLab Group (ACG) grew 2% on a core basis, with ex-China ACG growing at the high end of mid-single digits and consumables growing high single digits. By end market, Pharma grew 6%, with biotech growing low double digits and small molecule growing low single digits. Chemical and Advanced Materials (CAM) grew a robust 8%. Diagnostics and Clinical grew 11%. Environmental and Forensics delivered 13% growth, driven by forensics (greater than 50% growth) and environmental (low single-digit growth). Food declined 3%. Academia and Government declined 5%. Instrument revenue saw high single-digit growth, including low double-digit growth in LC, LC/MS, and GC. Specialty CDMO (Advanced Therapeutics) grew high single-digits. Cancer diagnostics grew low double digits, and pathology reagents saw strong double-digit growth.

Transcript Tidbits2 rows

2026-08-26

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketAgilent's advanced therapeutics division (ATD), including NASD and BIOVECTRA specialty CDMO operations, grew nearly 30%, expanding capacity and preparing for the next phase of growth. The company is well-positioned to benefit from biotech innovation in China, an inflection in contract testing laboratory volumes (especially food safety and materials exports, and PFAS testing), and the AI capital investment build-out in China, which plays into its strengths in GC, GC/MS, and spectroscopy. The recently launched 9500 Triple Quad ICP-MS is off to a strong start with semiconductor supply chain customers. Agilent launched its China Innovation Center and is co-developing lab automation software and partnering with a biotech company leveraging AI for drug discovery workflows. New Altura columns were launched for protein peptide therapeutics, large oligonucleotides, gene therapy, and vaccines, seeing 28% quarter-over-quarter growth in new biopharma accounts. The Omnis family continues to expand, bringing laboratory automation to new pathology customers, and the Biocare acquisition expands the clinically focused antibody menu. Use cases for the Raman Insight series expanded from airport security checkpoints to other cities in the U.S., with new Insight BRT and Insight300 aviation security products certified to latest detection standards. Initial pharma reshoring orders were booked in Q3, ahead of expectations, with revenue contributions building in fiscal 2027 and beyond, and the reshoring opportunity extends to semiconductor. GLP-1 momentum continues, delivering over 70% year-over-year growth in the quarter. Train C build-out is mechanically complete and expected to begin revenue generation next spring, with the majority of its capacity already booked. The mRNA modality has validated its real-world potential in oncology applications, which is seen as good news for analytical lab and CDMO businesses in the future.	About CompetitionAgilent's unparalleled customer intimacy and trust are translating into share gains across key workflows and geographies. The company secured competitive wins in China, including with two leading CXOs and an enterprise service contract with a marquee local pharma customer. A leading commercial testing lab in China chose Agilent over competition for PFAS testing needs, highlighting the strength of its differentiated portfolio and services. Agilent's complete end-to-end workflows for PFAS testing enable it to win against competition. The 9500 ICP-MS's value proposition (increased productivity, lower cost of ownership, ease of use) is resonating strongly, supporting customer technology migration. The reshoring opportunity in semiconductor is a key differentiator for Agilent compared to its peers. Agilent continues to win against the competition in all major geographies and expects to sustainably outperform them.	About The Broader IndustryEnd markets are steadily improving, with stronger funding environments translating into improved spending from small and mid-cap biotech customers. There is significant semiconductor investment and a broader AI infrastructure build-out expected over the near and medium term. Biotech innovation in China, combined with investment from global pharma companies, is creating meaningful demand for CXO customers. An inflection in contract testing laboratory volumes, particularly for food safety and materials exports, is being observed. The instrument replacement cycle continues, with an ample runway ahead for LC and GC. Early gains from reshoring dynamics are materializing, underpinning a sustainable multiyear instrument growth opportunity in pharma and semiconductor. The total biopharma financing rose to $60 billion in H1 2026, doubling from $30 billion, underpinned by a looming patent cliff, heightened demand for M&A, and licensing deals, leading to a return in small and mid-sized biotech spending. The mRNA modality has validated its real-world potential in oncology applications. The Middle East conflict and demand for memory chips continue to pressure costs across the industry.	Where Things Are HeadedAgilent anticipates continued strong commercial execution, renewed momentum in China, ongoing innovation, the instrument replacement cycle, pharma and semiconductor reshoring, and the compounding impact of the Ignite Operating System to drive future growth. The company expects continued expansion of the Altura column family for new use cases and is optimistic about expanding the Raman Insight series opportunity through further RFPs in the U.S. and adoption in Europe and beyond. More meaningful order benefits from pharma reshoring are expected around year-end, with revenue contributions building in fiscal 2027 and beyond. The robust growth in the advanced materials end market is expected to be underpinned by semiconductor investments and AI CapEx build-out over the medium term. Agilent is applying its disciplined approach to building next-generation digital and AI capabilities, leveraging AI to transform software development and accelerate differentiated software releases. The company expects full-year core growth of 5.8% to 6% for fiscal year 2026, approaching the midpoint of its long-range plan, and raised its full-year EPS expectations to $6.18 to $6.21. The Advanced Therapeutics Division (ATD) is expected to have flattish growth in Q4 due to tough year-over-year comparisons, but Train C is positioned to begin revenue generation next spring and ramp to full capacity over the next 6 to 8 quarters, with the majority of its capacity already booked. Agilent expects ongoing installed base expansion to fuel consumables uptake and service revenue growth. Full-year expectations for CAM, AMG, LDG, China, and Asia ex-China growth have been raised. The full-year operating margin expansion target (ex-tariff refunds) is increased to over 100 basis points. Q4 reported revenue is guided to be $1.98 billion to $2 billion, representing 5.2% to 6.2% core growth, with EPS between $1.71 and $1.74. The company expects pricing momentum to continue into year-end and feels confident about 2027 and beyond, supported by the Ignite program.	Updates On ThemeLife	Broader Themes EmergingDigital transformation and AI-driven transformation of drug discovery and lab operations are emerging as broader themes. Agilent is building next-generation digital and AI capabilities, leveraging AI to transform software development, shorten the software development life cycle, and improve decision-making and work processes. The company has mobilized partnerships with OpenAI and BCG X and is building an Agilent AI center of excellence. Sustainability is also a broader theme, with Agilent programmatically embedding it in facility design, engineering projects, and product design, leading to external recognition such as being named one of TIME's World's Most Sustainable Companies and Newsweek's World's Greenest Companies in 2026, an MSCI ESG upgrade to AAA, and joining the United Nations Global Compact.	Bullish-Leaning Quotes (Short)We delivered an excellent third quarter with strong performance on both the top and bottom lines. Our results clearly demonstrate the sustained momentum unlocked by our exceptional commercial and operational execution. Agilent reported $1.88 billion in revenue, growing 7.3% on a core basis and exceeding the high end of our guidance by 140 basis points. Our earnings per share of $1.56 on an ex refund basis were $0.06 above the high end of our guidance range. Pharma grew 12% in the quarter, well ahead of our high single-digit expectations and growth rates reported by our peers. Our advanced therapeutics division... grew nearly 30%. The improving end market picture was complemented by a notable step-up in China, which grew 9%, well ahead of our flat expectation. Our recent product launches at the ASMS conference in June are all off to a strong start. Q3 book-to-bill came in above 1, marking the 10th consecutive quarter where instrument orders met or grew faster than revenue. Our strategic pricing initiatives delivered approximately 200 basis points in Q3. We're generating more returns on every incremental revenue dollar, giving us financial flexibility. Agilent was named as TIME's World's Most Sustainable Companies and Newsweek's World's Greenest Companies in 2026. Our GLP-1 momentum continues, delivering more than 70% year-over-year growth in the quarter. Our full year growth is now poised to approach the midpoint of our long-range plan. Fiscal year '26 earnings per share are now expected to be between $6.12 and $6.15, representing robust earnings growth of 10%.	Bearish-Leaning Quotes (Short)Diagnostics and clinical grew at the high end of the mid-single-digit range, slightly below our high single-digit guide. Food was roughly flat in the quarter, ahead of our expectations for a low single-digit decline. Academic and government, our smallest end market, declined 3%, modestly below our expectations. We expect flattish growth in ATD in the fourth quarter when the segment laps a tough year-over-year compare of over 40%. While the Middle East conflict and demand for memory chips continue to pressure our costs. Europe grew low single digits on a tough year-over-year compare. Our fourth quarter guide does not include any future benefit from potential tariff refunds.	HiringAgilent achieved rapid factory turnaround and responded to demand faster without adding headcount, despite navigating rising material costs and supply chain headwinds. For the Train C build-out in the CDMO business, Agilent will be hiring staff in advance of the facility coming online next spring.

2026-05-27

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketAgilent is expanding its eligible market through the deployment of new bulk alarm resolution technology at airport security checkpoints for the TSA, with opportunities to apply this technology more broadly. The new 9,500 triple quad ICPMS brings advanced capabilities to a broader customer base by addressing pain points around throughput, workflow complexity, and operating costs. New Altura columns are targeted to address workflows for protein and peptide therapeutics, large oligos, gene therapy, and vaccines. The company is launching a China Innovation Center to strengthen R&D capabilities across emerging areas like digital, AI, and automation. The Biocare acquisition will strengthen the cancer diagnostics business by adding Biocare's clinically focused antibody menu. AI is seen as a tremendous growth driver for the life sciences industry, accelerating drug development and increasing demand for large-scale multimodal data sets and investments in the wet lab.	About CompetitionAgilent emphasizes its extraordinary level of customer intimacy and trust as a differentiator from the competition, which is increasingly translating into share gains across key workflows and geographies. The company is winning outsized shares in forensics, including multiple competitive large tender wins in Asia and Europe, driven by its unique technology. Agilent reported market-leading low double-digit growth in LC and LC/MS and in GC, with share gains driven by customer-centric innovation. The company's customer-centric approach is validated by industry market share data, showing continued wins against competition in all major geographies. Agilent is the #1 player in the Chemical and Advanced Materials (CAM) market by far, with substantial leadership positions in GC, GC/MS, and spectroscopy. The company expects to sustainably outperform the competition.	About The Broader IndustryThe broader industry is characterized by a continued instrument replacement cycle and healthy demand across key end markets. Strong semiconductor demand and healthy chemical CapEx investments are noted in the Americas. Positive demand signals are beginning to emerge from small to mid-cap biotech companies. The current helium supply environment is making productivity and resource efficiency benefits increasingly valuable for customers. AI is identified as a tremendous growth driver for the life sciences industry, with pharma customers leveraging it to accelerate drug development and reduce late-stage failures, leading to a growing need for large-scale multimodal data sets and wet lab investments. There are ongoing plans for pharma customers to reshore operations to the U.S. The Middle East conflict is causing logistics challenges, material shortages, and inflationary cost pressures, and the demand for memory chips is also putting upward pressure on costs. The second half of the fiscal year faces increasingly tougher comparisons. The food market is influenced by ever-changing food safety regulations, customer demand for healthier and sustainable alternative foods, and increased sample volumes at contract labs, with emerging PFAS in food noted as a strong growth area. Biotech funding recovery is translating into increased bioprocessing orders, while surging GLP-1 and biologics demand fuels high-value solutions. Pharma reshoring continues to benefit CDMOs and capacity expansions.	Where Things Are HeadedAgilent expects operational improvements to increasingly support higher quality and durable earnings growth. The company anticipates continued instrument strength and is looking forward to a next wave of innovations to support durable growth, strengthen its installed base, and drive recurring consumables and services pull-through, with new launches showcased at ASMS. The 9,500 ICPMS is expected to serve as a differentiated architecture for ICPMS growth well into the future. New Altura columns will target protein and peptide therapeutics, large oligos, gene therapy, and vaccines workflows. The China Innovation Center aims to strengthen R&D in digital, AI, and automation. The Ignite operating system is poised to deliver compounding benefits in the years to come, with AI being a key FY '26 enterprise focus area. Initial orders for pharma reshoring to the U.S. are expected by the end of the fiscal year, with revenue starting in FY '27. Agilent raised its full-year core growth guidance to 4.5% to 6% and EPS guidance to $6.00 to $6.10. The company expects high single-digit growth in pharma and a low single-digit decline in academic and government. Expectations for chemicals and advanced materials, as well as diagnostics and clinical, have been raised to mid- to high single-digit growth. Environmental and forensics guidance is raised to low to mid-single-digit growth, while food guidance is lowered to a low single-digit decline. All three business segments are now expected to see mid-single-digit growth. Asia ex-China growth assumptions are increased to mid- to high single digits. The full-year operating margin expansion target is raised to 85 basis points. The China stimulus is expected to result in orders toward the end of the year, with revenue in the first part of next year, and Agilent expects mid-single to high single-digit growth for China in the long term. Capital expenditures are now expected to be approximately $450 million, down $50 million from prior guidance.	Updates On ThemeLife	Broader Themes EmergingDigital transformation, AI-driven transformation of drug discovery and lab operations, and automation are emerging as broader themes across the industry.	Bullish-Leaning Quotes (Short)We delivered an excellent second quarter with stronger-than-expected revenue growth, significant margin expansion and double-digit EPS growth. The strength was broad-based across our largest end markets and supported by continued replacement cycle momentum, innovation-led share gains and improving operational execution. Earnings per share of $1.49 represents 14% year-over-year growth, which also exceeded the top end of our guidance by $0.07. We delivered at or above our long-term plan on all metrics: revenue growth, margin expansion and EPS growth. Our unique technology is helping us win outsized shares of forensics, where we delivered greater than 50% growth in the quarter. Our commercial excellence delivered a book-to-bill above 1 again this quarter, marking the ninth consecutive quarter where instrument orders met or exceeded revenue. Ignite had a significant impact on the business on both the top and bottom lines during the quarter and is poised to deliver compounding benefits in the years to come. Our strategic pricing capability delivered approximately 200 basis points of pricing in Q2. AI has the potential to be a tremendous growth driver for the life sciences industry. Our GLP-1 momentum continues delivering about 20% growth year-to-date. Agilent will continue to sustainably outperform the competition.	Bearish-Leaning Quotes (Short)despite the macro and geopolitical environment. China declined 9%, a bit more than we had expected. Food, our second smallest end market declined 3% with softer-than-expected results in Asia due to funding delays in China and India. Academia and government, our smallest end market declined 5% in line with expectations. Middle East conflict in the demand for memory chips puts upward pressure on our costs. inflationary cost pressures during the remainder of the year. increasingly tougher comps. China A&G is very soft in the quarter on tightened and delayed government spend leading to lower academia stimulus. slower government funding and of course, pressure from the Middle East conflict on food shipments and testing in Asia is an incremental challenge.	HiringAgilent has increased capabilities and the level of talent throughout the organization. The company intends to strengthen its R&D capabilities across multiple emerging areas, including digital, AI, and automation, by leveraging China's deep base of technical talent and vibrant innovation ecosystem. Agilent is also looking forward to welcoming new colleagues to Agilent later this year as part of the Biocare acquisition. The operations organization has been reconfigured to a greater depth in planning, lean manufacturing, and digital engineering.

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	Price Reaction
2026-08-26	Agilent's Q3 2026 earnings exceeded expectations, driven by robust pharma growth (12%, 70%+ from GLP-1s), a significant China rebound (9%), and strong operational execution via the Ignite system. Management raised full-year guidance, and the stock outperformed SPY by 1.26% (1.68% vs. 0.42%) in the two days post-earnings, reflecting positive market perception of the strong results and optimistic outlook.	Earnings Transcript	Neutral		+1.68% (vs SPY: +1.26%)

Upcoming Events2 rows

Catalyst ID	Estimated Timing	Estimated Date Start	Estimated Date End	Catalyst	Why It Matters	Ticker Or Theme Specific	Transcript Date	Source Type
A_8bb5aafd	at the end of our fiscal year	2026-10-01	2026-10-31	Initial orders from large pharma customers for reshoring operations to the U.S.	This represents a strong tailwind for Agilent's downstream manufacturing QA/QC workflows, aligning with broader industry trends and potentially driving future revenue starting in FY27.	Ticker	2026-05-27	earnings_transcript
A_6dd05b00	later this year	2026-08-12	2026-12-31	Completion of the Biocare acquisition.	The acquisition is expected to provide robust long-term growth, strong strategic fit, and opportunities for synergy realization, making the financial returns highly attractive.	Ticker	2026-05-27	earnings_transcript